Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.65 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.65 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.65 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.65 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.65 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.65 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.65 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.52 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.52 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.52 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.52 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.52 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.52 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2251424 | 1.00 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL30571083 | 0.97 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL965272 | 0.97 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL93830 | 0.97 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29438088 | 0.97 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL30022755 | 0.97 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL93831 | 0.97 | GRM8 (0.68) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL10361106 | 0.95 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Bromide SCHEMBL31300189 | 0.95 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Water SCHEMBL2288176 | 0.95 | GRM8 (0.65) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119110730-A | Method for preparing Iglibenclamide and salt thereof | 哈曼菲诺化学有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118480552-B | SARNA for targeting CEBPA gene expression and application thereof | 成都先衍生物技术有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118480552-A | SARNA for targeting CEBPA gene expression and application thereof | 成都先衍生物技术有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4398942-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-07-17 | — | — | EP | disclosed |
| CN-115052594-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240228475-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| CN-118201642-A | Linker for antibody drug conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190841-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240190894-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | FOGHORN THERAPEUTICS INC. | 2024-06-13 | — | — | US | disclosed |
| CN-109913455-B | Small interfering RNA capable of treating cancer | 左志军 | 2024-05-28 | — | — | CN | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-10988508-B2 | Synthetic N-acetyl-muramic acid derivatives and uses thereof | UNIVERSITY OF DELAWARE (US) | 2021-04-27 | — | — | US | disclosed |
| CN-112601751-A | Fused thiophene compounds | 拜欧斯瑞克斯公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-111032628-A | Process for preparing tert-butyl (S) -4, 5-diamino-5-oxovalerate | 细胞基因公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-104718202-B | The method for being used to prepare (S) -3- (4- ((4- (morpholinyl methyl) benzyl) oxygroup) -1- oxoisoindolines -2- base) piperidine-2,6-diones and its pharmaceutically acceptable form | 细胞基因公司 | 2018-11-20 | — | — | CN | disclosed |
| US-20180298061-A1 | SYNTHETIC N-ACETYL-MURAMIC ACID DERIVATIVES AND USES THEREOF | UNIVERSITY OF DELAWARE (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2016172615-A1 | SYNTHETIC N-ACETYL-MURAMIC ACID DERIVATIVES AND USES THEREOF | UNIVERSITY OF DELAWARE (US) | 2016-10-27 | — | — | WO | disclosed |
| CN-104718202-A | Processes for the preparation of (S)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof | CELGENE CORP | 2015-06-17 | — | — | CN | disclosed |
| CN-1264810-C | Process for synthesis of L-glutamine | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2006-07-19 | — | — | CN | disclosed |
| CN-1569820-A | Process for synthesis of L-glutamine | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2005-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | GRIN2D 4521/4885GRIN3B 3550/4885GRIN1 3777/4885 |
| US-20240190841-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | GRIN2D 4727/4885GRIN3B 4467/4885GRIN1 4615/4885 |
| US-10988508-B2 | Synthetic N-acetyl-muramic acid derivatives and uses thereof | NOD2, NOD1, MYD88 | GRIN2D 1922/4885GRIN3B 2897/4885GRIN1 1125/4885 |
| US-20240190894-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | CS, SMARCC2, SMARCC1 | GRIN2D 4258/4885GRIN3B 3440/4885GRIN1 3548/4885 |
| US-20180298061-A1 | SYNTHETIC N-ACETYL-MURAMIC ACID DERIVATIVES AND USES THEREOF | NOD2, NOD1, MYD88 | GRIN2D 1922/4885GRIN3B 2897/4885GRIN1 1125/4885 |
| US-20240228475-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | AQP1, AQP3, ADH1C | GRIN2D 272/4885GRIN3B 2140/4885GRIN1 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.